Our Approach
At TG Therapeutics, we have a bold approach to develop novel medicines for patients with B-cell diseases, specifically autoimmune diseases.
Our process can be divided into 3 distinct steps: 1) Strategically identify genes and pathways known to drive the abnormal behavior of B-cells; 2) Acquire and optimize compounds with “best-in-class” potential; and 3) Develop medicines that have the potential to improve patient outcomes without compromising convenience.
This unique vision is enabled by:
––An exceptional internal team with a deep understanding of B-cell diseases and significant experience successfully pioneering innovative treatments for these complex diseases
––A vast external global network of community and academic clinical trial sites dedicated to research in B-cell diseases
MS
Learn more
IDENTIFY
Leveraging the expertise of our internal team and external collaborators, we strategically identify those genes and pathways known to drive the abnormal behavior of B-cells.
ACQUIRE
We acquire and optimize compounds with “best-in-class” potential with the goal of bringing new treatments to patients that are highly effective, safe, and convenient. We do this by seeking out rationally designed drug candidates from academic centers of excellence or compounds in development at biotechnology or pharmaceutical companies.
DEVELOP
Relying on our deep understanding of B-cell physiology, disease pathogenesis, and pharmacology, our drug development team begins the process of identifying drugs that have the potential to improve patient outcomes without compromising convenience.